Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 2Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 878Pancreatic Neoplasms 572Carcinoma, Hepatocellular 542Stomach Neoplasms 512Esophageal Neoplasms 312Rectal Neoplasms 280Colonic Neoplasms 254Breast Neoplasms 203Neoplasms 201Liver Neoplasms 187Lung Neoplasms 174Carcinoma, Non-Small-Cell Lung 174Cholangiocarcinoma 153Ovarian Neoplasms 141Neoplasm Metastasis 135Gastrointestinal Neoplasms 133Esophageal Squamous Cell Carcinoma 130Melanoma 103Prostatic Neoplasms 98Biliary Tract Neoplasms 95Endometrial Neoplasms 83Uterine Cervical Neoplasms 79Head and Neck Neoplasms 72Squamous Cell Carcinoma of Head and Neck 69Carcinoma, Renal Cell 58Sarcoma 54Adenocarcinoma Of Esophagus 54Urinary Bladder Neoplasms 53Anus Neoplasms 52Triple Negative Breast Neoplasms 48

Interventions

trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Gastric Adenocarcinoma × Gastrointestinal × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡